Where is Qubis' headquarters located?

Qubis' headquarters is located in Belfast (United Kingdom).

How big is Qubis' investment team?

Qubis has a team of 16, including 9 partners.

How many companies has Qubis invested in?

Qubis has invested in 46 companies, including Cibus & Kainos Group.

Which companies has Qubis invested in lately?

AMPLY Discovery & StimOxyGen are the latest investments by Qubis.

How many exits has Qubis been involved in?

Qubis' portfolio has seen 4 IPOs and 4 acquisitions.

Qubis - 2026 Investor Profile, Portfolio, Team & Investment Trends

Qubis, an accelerator and incubator program founded in 1984, is based in Belfast, United Kingdom. With a presence in 2 countries, it has supported around 46 startups in sectors like Life Sciences, Enterprise Applications. As of Apr 2026, Qubis has witnessed 8 portfolio exits. Most notable companies in its portfolio include Cibus, Kainos Group and Nuada. The program is backed by a team of 16 people who primarily support Seed startups based in United Kingdom. Its latest investment was a $1.75M Seed round in AMPLY Discovery on May 01, 2025, which also saw participation from Twin Path Ventures and Venture Science.

Key Metrics

Founded Year

1984

Location

Belfast, United Kingdom

Portfolio Companies

Cibus, Kainos Group & 44 more

Sectors of Investment

Life Sciences, Enterprise Applications & 14 more

Stages of Investment

Seed, PE & 3 more

Locations of Investment

United Kingdom & United States

View Qubis's full profile

Qubis has a portfolio of 46 companies. Their most notable investments are in VascVersa and AMPLY Discovery.Their portfolio spans across United Kingdom and United States. They have invested in Life Sciences, Enterprise Applications, High Tech and 13 other sectors, across stages such as Seed, PE and 3 more. Here is the list of top investments by Qubis:

1. Cibus

Developer of precision breeding technologies for resilient and vigorous crops. The company focuses on creating crops with specific traits to withstand environmental stressors. It works with agricultural partners to develop seeds resistant to heat, pests, fungus, and weeds. The goal is to produce crops that require fewer chemicals and less energy.

Key facts about Cibus

Founded Year: 2001
Location: San Diego (United States)
Annual Revenue: $4.26M as on Dec 31, 2024
Stage: Public
Total Funding till date: $34.5M
Employee Count: 129 as on Dec 31, 2022
Investors: Fidelity Investments, Acks and 7 Others
Latest Funding Round: Post IPO, Apr 08, 2020, $*****
Highlight: Public

2. Kainos Group

Provider of web design, software development, data analytics, and digital transformation services. Its portfolio includes web & mobile application development, career development, product design, cloud management, AI, workday deployment, digital advisory, and enterprise content management services. It also offers various managed service models to suit different needs, including core and flexible support models.

Key facts about Kainos Group

Founded Year: 1986
Location: Belfast (United Kingdom)
Stage: Public
Employee Count: 2,606 as on Mar 31, 2023
Investors: Herald Investment Management, Qubis and 1 Other
Highlight: Public

3. Nuada

Provider of carbon capture technology solutions. It uses energy-efficient filtration machines that make carbon capture commercially viable and pave the path for zero carbon emissions in industry. It utilizes solid sorbent materials and operates via vacuum swing adsorption gas separation technology.

Key facts about Nuada

Founded Year: 2012
Location: Newtownabbey (United Kingdom)
Valuation: $*****
Stage: Series A
Total Funding till date: $12.8M
Employee Count: 29 as on Dec 31, 2024
Investors: BGF, Gov and 22 Others
Latest Funding Round: Grant (prize money), Apr 08, 2025, $*****
Highlight: Editors' Pick

4. Fusion Antibodies

Fusion Antibodies is a contract research organization offering a range of services in the antibody drug discovery and development space. The company's two antibodies are in clinical and preclinical trials. Services offered include antibody sequencing, antibody humanization, stable cell line development, antibody engineering, monoclonal antibody production, and transient protein expression.

Key facts about Fusion Antibodies

Founded Year: 2001
Location: Belfast (United Kingdom)
Stage: Public
Total Funding till date: $2.5M
Employee Count: 58 as on Mar 31, 2022
Investors: Viridian Investment Partners, Qubis and 4 Others
Latest Funding Round: Post IPO, Feb 14, 2024, $*****
Highlight: Public

5. Sonrai Analytics

Developer of software for data analytics and insights. The platform is offering AI and ML-based applications which enables users to filter and analyze data sets in real-time to provide results, predictions, or insights based on the analysis for precision medicine. It offers features such as data management, design workflows, data visualization, and many more.

Key facts about Sonrai Analytics

Founded Year: 2018
Location: Belfast (United Kingdom)
Stage: Seed
Total Funding till date: $3.56M
Employee Count: 16 as on Feb 28, 2022
Investors: Qubis, Forward Partners and 24 Others
Latest Funding Round: Seed, Sep 04, 2025, $*****
Highlight: Editors' Pick

View the full list of portfolio companies

Qubis has invested in 47 companies over the last 20 years, with an average of 2 new investments annually in the last 10 years. In 2025, it made 4 investments. Its most recent first time investment was in StimOxyGen and most recent follow-on round was in AMPLY Discovery.

Here are Qubis' Year-on-Year Investment Trends:

Year	No. of Investments
Year	1^st Round	Follow-on	Total
2026 (YTD)	0	0	0
2025	3	1	4
2024	1	0	1
2023	0	1	1
2022	5	4	9
2021	3	0	3
2020	3	0	3
2019	0	0	0
2018	2	0	2

View all investments by Qubis

Qubis has made 18 investments in Seed stage with an average round size of $1.2M, 1 investment in PE stage with an average round size of $2.5M, 1 investment in Post IPO stage with an average round size of $702K, 1 investment in Series A stage with an average round size of $5.63M and 1 investment in Series B stage with an average round size of $15.2M.

Here are Qubis' investments by stage:

Stage of entry	No. of Investments
Seed	18
PE	1
Post IPO	1
Series A	1
Series B	1

Note: We have considered here, only first round of investments

View all investments by Qubis

Qubis has a diverse portfolio, with companies operating in the Life Sciences, Enterprise Applications, HealthTech, High Tech and Food and Agriculture Tech. Notably, it has invested in 39 Enterprise (B2B) companies, 33 Tech companies, 16 Software companies and at least 8 companies focusing on Tech hardware.

Here are Qubis' investments by sector:

Sector	No. of Investments
Life Sciences	14
Enterprise Applications	7
HealthTech	6
High Tech	4
Food and Agriculture Tech	3
Others	11

Note: We have considered here, only first round of investments

View all investments by Qubis

Qubis has made most investments in United Kingdom (21), followed by United States where it has made 1 investment.

Here are Qubis' investments by geography:

Country	No. of Investments
United Kingdom	21
United States	1

Note: We have considered here, only first round of investments

View all investments by Qubis

Qubis has not made any investment in 2026 so far.

Here are the most recent investments by Qubis:

Filter this list

Date	Company	Location	Round Details	Round Amount	Co-Investors
May 01, 2025	AMPLY Discovery	United Kingdom	Seed	5493	Twin Path Ventures [+3]
Mar 11, 2025	StimOxyGen	United Kingdom	Seed	3716	DSW Ventures [+1]
Feb 25, 2025	RETìníZE	United Kingdom	Seed	1272	Techstart Ventures [+3]
Jan 13, 2025	Dia Beta Labs	United Kingdom	Seed	4887	DSW Ventures
Jun 19, 2024	TraitSeq	United Kingdom	Seed	7976	Deeptech Seed Fund

See more recent investments made by Qubis

4 of Qubis' portfolio companies have become public. Fusion Antibodies got listed on the London Stock Exchange (LSE), in Dec 2017 at marketcap of $36.5M and Cibus got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of undefined.

Here are Qubis' portfolio companies that went public:

Filter this list

Company	IPO Date	First Invested on	First Round of Investment	Round Size
Fusion Antibodies	Dec 18, 2017	Jul 26, 2007	PE	7842
Cibus	Jul 20, 2017	Apr 08, 2020	Post IPO	3695
Kainos Group	Jul 10, 2015	-	-	8042
Adoreboard	-	-	-	7212

View more details about public companies in Qubis' portfolio

4 companies from Qubis' portfolio have been acquired. The most recent acquisition were ProAxsis in Oct 2020 by NetScientific.

Here are Qubis' portfolio companies that got acquired most recently:

Filter this list

Company	Acquisition Date	First Invested on	First Round of Investment	Round Size
ProAxsis	Oct 16, 2020	-	-	1691
Titan IC	Mar 03, 2020	-	-	8364
PathXL	Jun 21, 2016	Apr 05, 2009	Seed	7502
Lagan Technologies	Oct 06, 2010	Jul 20, 2006	Series B	5122

View all acquired companies in Qubis' portfolio

Qubis has a team of 16 members including 9 Partners and 1 Principal located in United Kingdom. Qubis' team sits on the board of 1 company.

Here is a list of top team members in Qubis:

Name	Designation	Location	Board Memberships	Contact Details
Helen Kirkpatrick	Partner	Belfast	DisplayNote	-
Nicola Broughton	Partner	United Kingdom	-	1 Email
Louise Reed	Partner	United Kingdom	-	1 Email
Rotha Johnston	Partner	-	-	-
Eoin McMullan	Partner	Belfast	-	-
Archie Clements	Partner	United Kingdom	-	-
Stuart Elborn	Partner	Belfast	-	-
David Quinn	Partner	Hillsborough	-	-
Andrew Norton	Partner	Belfast	-	1 Email
Anne Dornan	Principal	Manchester	-	1 Email

View team details of Qubis

Over the past 20 years, 93 investors have co-invested in Qubis's portfolio companies. This includes funds and angels.

Invested before Qubis: Adama, Fidelity Investments and 11 others have invested in rounds before Qubis. There is 1 company where Adama has invested before Qubis and 1 company where Fidelity Investments has invested before Qubis.
Top Co-investors of Qubis: 38 investors entered a company along with Qubis. These include investors like Invest Northern Ireland (6 companies).
Invested after Qubis: A total of 42 investors have invested in Qubis's portfolio after their investments. Top Investors include Clarendon Fund Managers (4 companies) and Invest Northern Ireland (2 companies).